Current and Emerging Therapeutic Approaches for Colorectal Cancer: A Comprehensive Review

Overview

Journal World J Gastrointest Surg

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2023 May 19

PMID 37206081

Authors

Anil Kumar

Vipasha Gautam

Arushi Sandhu

Kajal Rawat

Antika Sharma

Lekha Saha

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) affects 1 in 23 males and 1 in 25 females, making it the third most common cancer. With roughly 608000 deaths worldwide, CRC accounts for 8% of all cancer-related deaths, making it the second most common cause of death due to cancer. Standard and conventional CRC treatments include surgical expurgation for resectable CRC and radiotherapy, chemotherapy, immunotherapy, and their combinational regimen for non-resectable CRC. Despite these tactics, nearly half of patients develop incurable recurring CRC. Cancer cells resist the effects of chemotherapeutic drugs in a variety of ways, including drug inactivation, drug influx and efflux modifications, and ATP-binding cassette transporter overexpression. These constraints necessitate the development of new target-specific therapeutic strategies. Emerging therapeutic approaches, such as targeted immune boosting therapies, non-coding RNA-based therapies, probiotics, natural products, oncolytic viral therapies, and biomarker-driven therapies, have shown promising results in preclinical and clinical studies. We tethered the entire evolutionary trends in the development of CRC treatments in this review and discussed the potential of new therapies and how they might be used in conjunction with conventional treatments as well as their advantages and drawbacks as future medicines.

Citing Articles

Nano-Radiopharmaceuticals in Colon Cancer: Current Applications, Challenges, and Future Directions.

Alkatheeri A, Salih S, Kamil N, Alnuaimi S, Abuzar M, Abdelrahman S Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006069 PMC: 11859487. DOI: 10.3390/ph18020257.

Green Tea Components: In Vitro and In Vivo Evidence for Their Anticancer Potential in Colon Cancer.

Randisi F, Perletti G, Marras E, Gariboldi M Cancers (Basel). 2025; 17(4).

PMID: 40002218 PMC: 11853328. DOI: 10.3390/cancers17040623.

Exploring the anti-metastatic potential of sunitinib and novel analogs in colorectal cancer: insights into HIF-1α mediated metastasis.

Rassouli F, Matin M, Hadizadeh F, Nejabat M, Allahverdizadeh H, Jamali H Front Pharmacol. 2025; 16:1520881.

PMID: 39968177 PMC: 11832664. DOI: 10.3389/fphar.2025.1520881.

Understanding microRNA-Mediated Chemoresistance in Colorectal Cancer Treatment.

Valenzuela G, Contreras H, Marcelain K, Burotto M, Gonzalez-Montero J Int J Mol Sci. 2025; 26(3).

PMID: 39940936 PMC: 11818086. DOI: 10.3390/ijms26031168.

The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy.

Meyiah A, Khan F, Alfaki D, Murshed K, Raza A, Elkord E Transl Oncol. 2025; 53:102307.

PMID: 39904281 PMC: 11846588. DOI: 10.1016/j.tranon.2025.102307.

References

Roth M, Eng C . Neoadjuvant Chemotherapy for Colon Cancer. Cancers (Basel). 2020; 12(9). PMC: 7564118. DOI: 10.3390/cancers12092368. View

Kara G, Calin G, Ozpolat B . RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022; 182:114113. DOI: 10.1016/j.addr.2022.114113. View

Kana S, Essani K . Immuno-Oncolytic Viruses: Emerging Options in the Treatment of Colorectal Cancer. Mol Diagn Ther. 2021; 25(3):301-313. DOI: 10.1007/s40291-021-00517-7. View

Johnson J, Mukhtar H . Curcumin for chemoprevention of colon cancer. Cancer Lett. 2007; 255(2):170-81. DOI: 10.1016/j.canlet.2007.03.005. View

Kershaw M, Wang G, Westwood J, Pachynski R, Tiffany H, Marincola F . Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 2002; 13(16):1971-80. DOI: 10.1089/10430340260355374. View

Atkins M, Lotze M, Dutcher J, Fisher R, Weiss G, Margolin K . High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17(7):2105-16. DOI: 10.1200/JCO.1999.17.7.2105. View

Lee T, Lee K, Chen S, Chang H . 6-Gingerol inhibits ROS and iNOS through the suppression of PKC-alpha and NF-kappaB pathways in lipopolysaccharide-stimulated mouse macrophages. Biochem Biophys Res Commun. 2009; 382(1):134-9. DOI: 10.1016/j.bbrc.2009.02.160. View

Pokrovska T, Jacobus E, Puliyadi R, Prevo R, Frost S, Dyer A . External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase. Cancers (Basel). 2020; 12(4). PMC: 7226394. DOI: 10.3390/cancers12040798. View

Ahsan A, Ramanand S, Bergin I, Zhao L, Whitehead C, Rehemtulla A . Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts. Neoplasia. 2014; 16(2):105-14. PMC: 3978391. DOI: 10.1593/neo.14182. View

10.

Li X, Zhou J, Chen Z, Chng W . P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation. World J Gastroenterol. 2015; 21(1):84-93. PMC: 4284363. DOI: 10.3748/wjg.v21.i1.84. View

11.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

12.

Bharti A, Donato N, Aggarwal B . Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol. 2003; 171(7):3863-71. DOI: 10.4049/jimmunol.171.7.3863. View

13.

Modi V, Dunbrack Jr R . A Structurally-Validated Multiple Sequence Alignment of 497 Human Protein Kinase Domains. Sci Rep. 2019; 9(1):19790. PMC: 6930252. DOI: 10.1038/s41598-019-56499-4. View

14.

Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M . Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother. 2007; 30(7):762-72. DOI: 10.1097/CJI.0b013e318133451c. View

15.

Chanmee T, Ontong P, Konno K, Itano N . Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel). 2014; 6(3):1670-90. PMC: 4190561. DOI: 10.3390/cancers6031670. View

16.

Jacouton E, Chain F, Sokol H, Langella P, Bermudez-Humaran L . Probiotic Strain BL23 Prevents Colitis-Associated Colorectal Cancer. Front Immunol. 2017; 8:1553. PMC: 5702231. DOI: 10.3389/fimmu.2017.01553. View

17.

Taniguchi H, Iwasa S, Yamazaki K, Yoshino T, Kiryu C, Naka Y . Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer. Cancer Sci. 2017; 108(5):1013-1021. PMC: 5448625. DOI: 10.1111/cas.13227. View

18.

Prados J, Melguizo C, Roldan H, Alvarez P, Ortiz R, Arias J . RNA interference in the treatment of colon cancer. BioDrugs. 2013; 27(4):317-27. DOI: 10.1007/s40259-013-0019-4. View

19.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

20.

Latchman J, Guastella A, Tofthagen C . 5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice. Clin J Oncol Nurs. 2014; 18(5):581-5. PMC: 5469441. DOI: 10.1188/14.CJON.581-585. View